Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RXRX Recursion Pharmaceuticals, Inc.

Closed 11-13 16:00:00 EST

3.19

-0.14

-4.35%

盘后3.18

-0.01-0.16%

19:59 EST

High3.34	Low3.16	Vol16.72M
Open3.33	D1 Closing3.33	Amplitude5.41%
Mkt Cap1.98B	Tradable Cap1.93B	Total Shares622.76M
T/O53.86M	T/O Rate2.76%	Tradable Shares605.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":3.185,"timestamp":1794603600000,"preClose":3.33,"halted":0,"volume":16719541,"hourTrading":{"tag":"盘后","latestPrice":3.1799,"preClose":3.185,"latestTime":"19:59 EST","volume":356691,"amount":1132859.6252,"timestamp":1794617977054,"change":-0.0051,"changeRate":-0.001601,"amplitude":0.016264},"delay":0,"changeRate":-0.04354354354354355,"floatShares":605785384,"shares":622759259,"eps":-0.894456,"marketStatus":"Closed","change":-0.145,"latestTime":"11-13 16:00:00 EST","open":3.33,"high":3.34,"low":3.16,"amount":53855564.308215,"amplitude":0.054054,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.894456,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":5,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":3.33,"preHourTrading":{"tag":"盘前","latestPrice":3.33,"preClose":3.33,"latestTime":"09:29 EST","volume":152399,"amount":513344.40345630003,"timestamp":1794580185000,"change":0,"changeRate":0,"amplitude":0.024024},"postHourTrading":{"tag":"盘后","latestPrice":3.1799,"preClose":3.185,"latestTime":"19:59 EST","volume":356691,"amount":1132859.6252,"timestamp":1794617977054,"change":-0.0051,"changeRate":-0.001601,"amplitude":0.016264},"volumeRatio":0.906533,"impliedVol":0.9853,"impliedVolPercentile":0.7968},"requestUrl":"/m/hq/s/RXRX/tweets","defaultTab":"tweets","newsList":[{"id":"1112960877","title":"Movement Alert｜Recursion Pharmaceuticals, Inc. falls 5.11% in Regular Trading, market continues to reassess REC-4881 registrational trial path after data-driven rally fades","url":"https://stock-news.laohu8.com/highlight/detail?id=1112960877","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112960877?lang=en_us&edition=fundamental","pubTime":"2026-11-14 00:19","pubTimestamp":1794586752,"startTime":"0","endTime":"0","summary":"On November 14, Recursion Pharmaceuticals, Inc. fell 5.11% in Regular Trading, trading at $3.165 per share, with turnover of $20.9625 million.The clearest catalyst cited in recent market updates is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion falls as REC-4881 registrational path reassessed","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683454726","title":"Durable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2683454726","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683454726?lang=en_us&edition=fundamental","pubTime":"2026-11-13 10:26","pubTimestamp":1794536807,"startTime":"0","endTime":"0","summary":"MMitch LawlerNovember 13, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/durable-trial-results-might-change-the-case-for-recursion-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/durable-trial-results-might-change-the-case-for-recursion-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","RXRX","BK4611","BK4609","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177740016","title":"Movement Alert｜Recursion Pharmaceuticals, Inc. Intraday Decline 7.52%, market reassesses REC-4881 registrational path after prior data-driven rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1177740016","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177740016?lang=en_us&edition=fundamental","pubTime":"2026-11-12 23:00","pubTimestamp":1794495633,"startTime":"0","endTime":"0","summary":"On November 12, Recursion Pharmaceuticals, Inc. fell 7.52% in Regular Trading, trading at $3.3801 per share, with turnover of $20.4921 million.The clearest catalyst cited in recent market updates is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion slumps as market reassesses REC-4881 registrational path","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151769584","title":"Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 5.01% in Pre-Market Trading, Market Reassesses REC-4881 Registrational Path After Prior Data-Driven Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=1151769584","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151769584?lang=en_us&edition=fundamental","pubTime":"2026-11-12 22:23","pubTimestamp":1794493416,"startTime":"0","endTime":"0","summary":"On November 12, Recursion Pharmaceuticals, Inc. fell 5.01% in Pre-Market Trading, trading at $3.4195 per share, with turnover of $1.0612 million.The most direct backdrop is a market reassessment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Falls as Market Reassesses REC-4881 Path","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156893698","title":"Movement Alert｜Recursion Pharmaceuticals, Inc. Pre-Market Rise 5.07%, REC-4881 Phase 2 Data and Registrational Trial Plan Draw Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=1156893698","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156893698?lang=en_us&edition=fundamental","pubTime":"2026-11-11 21:05","pubTimestamp":1794402318,"startTime":"0","endTime":"0","summary":"On November 11, Recursion Pharmaceuticals, Inc. rose 5.07% in Pre-Market Trading, trading at $3.73 per share, with turnover of $1.5814 million.The clearest catalyst was the company’s newly disclosed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"REC-4881 Phase 2 Polyp Reduction Fuels Pre-Market Rally","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682330472","title":"Recursion Pharmaceuticals Plans to Attend Three Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2682330472","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682330472?lang=en_us&edition=fundamental","pubTime":"2026-11-11 21:03","pubTimestamp":1794402201,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Plans to Attend Three Healthcare Investor ConferencesRecursion will participate in the Jefferies Global Healthcare Conference London on Nov. 18, 2026.Participation in the Eve","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nNDL637NHk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","RXRX","BK4139","BK4539","BK4609","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682710387","title":"Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2682710387","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682710387?lang=en_us&edition=fundamental","pubTime":"2026-11-10 00:37","pubTimestamp":1794242247,"startTime":"0","endTime":"0","summary":"Iambic Therapeutics'  clinical data from the IAM1363 cancer trial and multiple high-value partnerships validate its artificial intelligence platform, BofA Securities said in a Monday note.Analysts said Iambic's more than $2 billion in investments from Takeda , AbbVie , Bayer, and RevMed shows that the industry values the platform.Iambic trades below competitors like Recursion Pharmaceuticals  and Schrodinger , and faces upside potential, BofA said.\"AI may eventually lower development costs, but today Iambic must fund both its technology and a growing pipeline,\" analysts said.BofA initiated coverage on the stock with a buy rating and a $30 price target.Shares of the company were up 30% in Monday trading.Price: 13.11, Change: +2.94, Percent Change: +28.86","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AIPO","BK4581","ABBV","LU0868494708.USD","VTHR","SDGR","IXJ","LU0310799852.SGD","BK7091","LU0545039389.USD","RXRX","LU0128525929.USD","XLV","PJP","ARTY","LU0203347892.USD","IE00BBT3K403.USD","FTXH","BK4609","AGIX","IYH","LU0211327993.USD","LU2129689514.USD","IAM","LU1839511570.USD","MEDX","BK4534","LU2237443465.HKD","TRUH","TAK","JDOC","LU0058720904.USD","QTOC","LU1989772923.USD","BK4548","LU1732800096.USD","PPH","RXL","FHLC","VHT","GLAM","CHAT","LU1934455277.USD","AGNG","IE00BVYPNW00.USD","LU0820561909.HKD","LU0738911758.USD","LU1929549753.HKD","IAM.AU","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682821872","title":"Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2682821872","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682821872?lang=en_us&edition=fundamental","pubTime":"2026-11-09 06:17","pubTimestamp":1794176267,"startTime":"0","endTime":"0","summary":"BBailey PembertonNovember 8, 2026","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-after-phase-2-data-what-the-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-after-phase-2-data-what-the-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4609","BK4548","BK4611","BK4539","RXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681508887","title":"Recursion Stock Gets A Lift From Trial Progress And New Board Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2681508887","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681508887?lang=en_us&edition=fundamental","pubTime":"2026-11-06 09:24","pubTimestamp":1793928243,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 6, 2026","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-stock-gets-a-lift-from-trial-progress-and-new-boar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-stock-gets-a-lift-from-trial-progress-and-new-boar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RXRX","BK4611","BK4539","BK4548","BK4139","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681099176","title":"Recursion Pharmaceuticals Grants Director Fred Hassan 156,658 Restricted Stock Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2681099176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681099176?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:39","pubTimestamp":1793831977,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Grants Director Fred Hassan 156,658 Restricted Stock UnitsRecursion Pharmaceuticals awarded director Fred Hassan 156,658 shares of Class A Common Stock on Nov. 2, 2026.Discla","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL67WLD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RXRX","BK4548","BK4139","BK4609","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681099179","title":"Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2681099179","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681099179?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:39","pubTimestamp":1793831963,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common SharesRecursion Pharmaceuticals director Blake Borgeson sold 40,000 shares of Class A Common Stock on November 3, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL9Vnswb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of $155,200 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","RXRX","BK4548","BK4139","BK4611","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680957387","title":"Recursion Pharmaceuticals Q3 Operating Revenue USD 18.055 Million Vs. IBES Estimate USD 14.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680957387","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680957387?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:44","pubTimestamp":1793655877,"startTime":"0","endTime":"0","summary":"Nov 02 (Reuters) - Recursion Pharmaceuticals Q3 operating income USD -123.176 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 02-NOV-202621:11:11.047 GMT","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nRSD1yBkgX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RXRX","BK4611","BK4548","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680289795","title":"Recursion Pharmaceuticals Q3 EPS $(0.22), Inline, Sales $18.552M Beat $14.783M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2680289795","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680289795?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:42","pubTimestamp":1793655730,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Q3 EPS $(0.22), Inline, Sales $18.552M Beat $14.783M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/RXRX","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4609","RXRX","BK4539","BK4611","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680795463","title":"Recursion Pharmaceuticals Q3 Net Loss Narrows More than Expected on Lower Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2680795463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680795463?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:40","pubTimestamp":1793655644,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Q3 net loss narrows more than expected on lower costsOverviewUS AI drug discovery firm's Q3 operating revenue rose, beating analyst expectationsQ3 net loss narrowed year-over","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL2N46J12A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RXRX","BK4548","BK4139","BK4609","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680930427","title":"Recursion Pharmaceuticals Q3 Pretax Profit USD -119.011 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680930427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680930427?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:30","pubTimestamp":1793655002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nPLXL6LPGP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4548","BK4611","BK4539","BK4139","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680799376","title":"Recursion Pharmaceuticals: Expected Cash Runway Extended into 2029; 2026 Cash Operating Expense Guidance < $375 Mln; 2027 < $360 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2680799376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680799376?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:30","pubTimestamp":1793655002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nPLXL6LPGP:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4611","RXRX","BK4548","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680179301","title":"Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in Rec-4881 and Rec-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2680179301","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680179301?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:30","pubTimestamp":1793655002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nTUA2XHTVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","RXRX","BK4611","BK4548","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680679535","title":"Press Release: Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2680679535","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680679535?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:30","pubTimestamp":1793655000,"startTime":"0","endTime":"0","summary":"-- New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult. population aged 18 years and older show deep, durable polyp burden. reductions in FAP, with activity throughout the GI tract and in larger,-- REC-4881 shows deep activity throughout the GI tract in post colectomy. patients, including near-clearance: After 12 weeks of treatment, nearly 1. in 2 patients in the upper GI and more than 1 in 3 in the lower GI. achieved polyp burden reductions of >=65%. Two patients achieved >=98%. -- REC-4881 reductions persisted off treatment: Twelve weeks after stopping. treatment, 85% of evaluable patients remained below baseline polyp. -- REC-4881 reductions in larger, higher-risk polyps: Six of eight patients. with polyps >5 mm at baseline had reductions in these polyp counts after. 12 weeks of treatment; four had reductions of at least 80%, including two. profile, with predominantly Grade 1/2 AEs, and no additional. confirmed partial responses in endometrial cancer, 1 unconfirmed p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4609","RXRX","BK4539","BK4611","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680793289","title":"New Phase 2 Rec-4881 Data Presented at Cga-IGC Show Deep, Durable Polyp Burden Reductions in Fap, with Activity Across the Gi Tract and in Larger, Higher-Risk Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2680793289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680793289?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:25","pubTimestamp":1793654709,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nFWN46J2QF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4139","BK4548","RXRX","BK4611","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680793209","title":"Recursion Pharmaceuticals - no New Safety Signals in Phase 2 Rec-4881; 81% Grade 1/2 Traes, 15% Grade 3, no Grade 4/5 Traes","url":"https://stock-news.laohu8.com/highlight/detail?id=2680793209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680793209?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:25","pubTimestamp":1793654709,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nFWN46J2QF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RXRX","BK4548","BK4609","BK4139","BK4539","BK4611"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.recursion.com;ir.recursion.com","stockEarnings":[{"period":"1week","weight":-0.0486},{"period":"1month","weight":-0.1317},{"period":"3month","weight":0.0538},{"period":"6month","weight":0.1365},{"period":"1year","weight":-0.2839},{"period":"ytd","weight":-0.1858}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035717},{"month":2,"riseRate":0.4,"avgChangeRate":0.049361},{"month":3,"riseRate":0,"avgChangeRate":-0.249219},{"month":4,"riseRate":0.4,"avgChangeRate":-0.090167},{"month":5,"riseRate":0.5,"avgChangeRate":0.076509},{"month":6,"riseRate":0.666667,"avgChangeRate":0.117519},{"month":7,"riseRate":0.666667,"avgChangeRate":0.141285},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.083252},{"month":9,"riseRate":0.5,"avgChangeRate":-0.006288},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.070009},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.004914},{"month":12,"riseRate":0.2,"avgChangeRate":-0.000986}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}